Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 8 months ago

Prevention & Chronic Conditions
HsCRP in ASCVD
Author(s): Adhya Mehta , Roger S Blumenthal , Ty J Gluckman , et al Added: 10 months ago

Prevention & Chronic Conditions
The WICD-MI Study
Author(s): Mathieu Echivard Added: 8 months ago
ESC HFA 25 - The WICD-MI study finds heart failure to be frequent in patients with persistent left ventricular dysfunction after acute myocardial infarction.We are joined onsite by Dr Mathieu Echivard (University Hospital of Nancy, Nancy, FR) to discuss key findings from a study investigating heart failure events in patients with persistent left ventricular dysfunction after acute myocardial… View more

Heart Failure

MI/ACS
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 10 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
Competitive Sports Participation for Athletes With CV Abnormalities
Author(s): Jonathan Ho-Youn Kim Added: 10 months ago
What is the importance of shared decision-making when counselling competitive athletes with cardiovascular abnormalities?In this short interview, Dr Jonathan Kim (Emory University, Atlanta, US) discusses the new scientific statement from AHA and ACC on clinical considerations for practitioners counselling competitive athletes with cardiovascular abnormalities. Dr Kim highlights the statement's… View more

Guidelines & Statements

Prevention & Chronic Conditions
Real-World Data for CV and Renal Outcomes in DKD
Author(s): David Wheeler Added: 7 months ago
ERA 2025 - Prof David Wheeler (University College London, London, UK) joins us to discuss outcomes from real-world data investigating cardiovascular and renal outcomes in patients with DKD.Interview Questions:1. How do real-world cardiovascular and renal outcomes compare to clinical trial results, and which data sources are giving us the best insights into DKD outcomes?2. What's the biggest gap… View more

Cardiovascular Renal Metabolic
Author(s): Billy A Caceres Added: 2 years ago
Dr Billy A Caceres (Columbia University School of Nursing, US), a renowned expert and lead author, recently discussed findings from the study titled "Differences in Ideal Cardiovascular Health Between Sexual Minority and Heterosexual Adults" published in JAMA Cardiology. The study aimed to determine whether there are disparities in cumulative cardiovascular health (CVH) scores between sexual… View more

Demographic
Sex and Gender in Research
Author(s): Kadijah F Porter , Brototo Deb , Andriy Katyukha , et al Added: 1 year ago

Demographic

Prevention & Chronic Conditions
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 4 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements